Comera Life Sciences, Inc.

7 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Reform Biologics, LLC (to 2022)

Ending by 2030

Jun 2035

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 30, 2026
The maintenance fee for Viscosity-reducing excipient compounds for protein formulations (US 11,660,343) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
1 fee due Dec 13, 2026
The maintenance fee for Viscosity-reducing excipient compounds for protein formulations (US 11,672,865) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
1 fee due Jan 11, 2027
The maintenance fee for Viscosity-reducing compounds for protein formulations (US 11,696,951) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
2 fees due May 7 to 19, 2027 · next May 7
1 fee due Oct 7, 2027
The maintenance fee for Stabilizing excipients for therapeutic protein formulations (US 10,610,600) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Patent	Title	Status	Expires	Confidence
US 11,660,343	Viscosity-reducing excipient compounds for protein formulations In force Ends no later than Jun 19, 2035 · From the USPTO record	In force	Ends no later than Jun 19, 2035	From the USPTO record
US 11,672,865	Viscosity-reducing excipient compounds for protein formulations In force Ends no later than Jun 19, 2035 · From the USPTO record	In force	Ends no later than Jun 19, 2035	From the USPTO record
US 11,806,399	Excipient compounds for biopolymer formulations In force Ends no later than Jun 19, 2035 · From the USPTO record	In force	Ends no later than Jun 19, 2035	From the USPTO record
US 10,478,498	Excipient compounds for biopolymer formulations In force Term ends Aug 5, 2035 · From the USPTO record	In force	Term ends Aug 5, 2035	From the USPTO record
US 11,696,951	Viscosity-reducing compounds for protein formulations In force Term ends Oct 20, 2036 · From the USPTO record	In force	Term ends Oct 20, 2036	From the USPTO record
US 10,279,048	Stabilizing Excipients for Therapeutic Protein Formulations In force Term ends Jul 12, 2037 · High confidence	In force	Term ends Jul 12, 2037	High confidence
US 10,610,600	Stabilizing excipients for therapeutic protein formulations In force Ends no later than Jul 12, 2037 · From the USPTO record	In force	Ends no later than Jul 12, 2037	From the USPTO record

Also on record, not counted in the 7: 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 5 no status recorded

List them